Core Viewpoint - The company Shijiazhuang Four Medicines Group has received medical device registration certificates for two products from the Hebei Provincial Drug Administration in China, indicating a significant step in expanding its product offerings in the medical device sector [1]. Group 1: Product Details - The medical recombinant collagen gynecological gel is designed to prevent the colonization of pathogenic microorganisms on the vaginal wall [1]. - The B-type natriuretic peptide (BNP) test kit is intended for the quantitative measurement of BNP levels in human plasma and whole blood samples, serving as an auxiliary diagnostic tool for assessing the risk of heart failure [1].

医用重组胶原蛋白妇科凝胶主要用于阻止病原微生物定植阴道壁，而B型利钠肽(BNP)检测试剂盒主要 用于透过体外定量测定人血浆和全血样本中B型利钠肽(BNP)的含量作为心力衰竭的辅助诊断风险评 估。 智通财经APP讯，石四药集团(02005)发布公告，本集团的医用重组胶原蛋白妇科凝胶及B型利钠肽 (BNP)检测试剂盒(萤光免疫层析法)两款医疗器械产品已获中国河北省药品监督管理局颁发医疗器械注 册证。 ...

Core Viewpoint - The company Shijiazhuang Four Medicines Group has received medical device registration certificates for two products from the Hebei Provincial Drug Administration in China, indicating regulatory approval for their medical devices [1] Group 1: Product Details - The medical recombinant collagen gynecological gel is designed to prevent pathogenic microorganisms from colonizing the vaginal wall [1] - The B-type natriuretic peptide (BNP) test kit is intended for the quantitative measurement of BNP levels in human plasma and whole blood samples, serving as an auxiliary diagnostic risk assessment for heart failure [1]

醫用重組膠原蛋白婦科凝膠主要用於阻止病原微生物定植陰道壁，而 B 型利鈉肽（BNP）檢測 試劑盒主要用於透過體外定量測定人血漿和全血樣本中 B 型利鈉肽（BNP）的含量作為心力衰 竭的輔助診斷風險評估。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的醫用重組膠原蛋白婦科凝膠及 B 型利鈉肽（BNP）檢測試劑盒（螢光免疫層析法） 兩款醫療器械產品已獲中國河北省藥品監督管理局頒發醫療器械注冊證。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年二月二十七日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...